Valproate as a mainstay of therapy for pediatric epilepsy

Renzo Guerrini

doi:10.2165/00148581-200608020-00004

Valproate as a mainstay of therapy for pediatric epilepsy

Renzo Guerrini

Fondazione Stella Maris

Research output: Contribution to journal › Article › peer-review

Abstract

This article reviews relevant pharmacologic and clinical information gathered for valproate since it was introduced into clinical practice 37 years ago and the application of this information for the treatment of childhood epilepsy. Valproate is available for oral and parenteral use. Oral forms are almost completely bioavailable but the rate of absorption varies between formulations. The Chrono® tablet formulation has not been adapted for children aged

Original language	English
Pages (from-to)	113-129
Number of pages	17
Journal	Pediatric Drugs
Volume	8
Issue number	2
DOIs	https://doi.org/10.2165/00148581-200608020-00004
Publication status	Published - 2006

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Pharmacology

Access to Document

10.2165/00148581-200608020-00004

Cite this

@article{2c1459695f144f01b93b79b0dca293ad,

title = "Valproate as a mainstay of therapy for pediatric epilepsy",

abstract = "This article reviews relevant pharmacologic and clinical information gathered for valproate since it was introduced into clinical practice 37 years ago and the application of this information for the treatment of childhood epilepsy. Valproate is available for oral and parenteral use. Oral forms are almost completely bioavailable but the rate of absorption varies between formulations. The Chrono{\textregistered} tablet formulation has not been adapted for children aged ",

author = "Renzo Guerrini",

year = "2006",

doi = "10.2165/00148581-200608020-00004",

language = "English",

volume = "8",

pages = "113--129",

journal = "Paediatric Drugs",

issn = "1174-5878",

publisher = "Adis International Ltd",

number = "2",

}

TY - JOUR

T1 - Valproate as a mainstay of therapy for pediatric epilepsy

AU - Guerrini, Renzo

PY - 2006

Y1 - 2006

N2 - This article reviews relevant pharmacologic and clinical information gathered for valproate since it was introduced into clinical practice 37 years ago and the application of this information for the treatment of childhood epilepsy. Valproate is available for oral and parenteral use. Oral forms are almost completely bioavailable but the rate of absorption varies between formulations. The Chrono® tablet formulation has not been adapted for children aged

AB - This article reviews relevant pharmacologic and clinical information gathered for valproate since it was introduced into clinical practice 37 years ago and the application of this information for the treatment of childhood epilepsy. Valproate is available for oral and parenteral use. Oral forms are almost completely bioavailable but the rate of absorption varies between formulations. The Chrono® tablet formulation has not been adapted for children aged

UR - http://www.scopus.com/inward/record.url?scp=33645848937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645848937&partnerID=8YFLogxK

U2 - 10.2165/00148581-200608020-00004

DO - 10.2165/00148581-200608020-00004

M3 - Article

C2 - 16608372

AN - SCOPUS:33645848937

VL - 8

SP - 113

EP - 129

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

IS - 2

ER -

Valproate as a mainstay of therapy for pediatric epilepsy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this